Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 6/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.35 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888251 | 0.93 | ATM (0.61) | ATMHCAR2HPGDTSHRMAPT | |
| SCHEMBL4892532 | 0.90 | ATM (0.61) | ATMHCAR2HPGDTSHRMAPT | |
| SCHEMBL4888226 | 0.90 | HCAR2 (0.47) | ATMHCAR2HPGDTSHRMAPT | |
| SCHEMBL4888287 | 0.90 | HCAR2 (0.47) | ATMHCAR2HPGDTSHRMAPT | |
| SCHEMBL4888147 | 0.88 | ATM (0.48) | ATMHCAR2HPGDTSHRMAPT | |
| SCHEMBL35576 | 0.87 | ATM (0.56) | ATMHCAR2HPGDTSHRMAPT | |
| SCHEMBL4889702 | 0.87 | ATM (0.56) | ATMHCAR2HPGDTSHRMAPT | |
| SCHEMBL24797 | 0.86 | ATM (0.70) | ATMHCAR2HPGDTSHRMAPT | |
| SCHEMBL21999255 | 0.86 | HCAR2 (0.59) | ATMHCAR2HPGDTSHRMAPT | |
| SCHEMBL167356 | 0.86 | HCAR2 (0.59) | ATMHCAR2HPGDTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113874459-A | Flexible photocurable cyanoacrylate compositions | 汉高知识产权控股有限责任公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-105246872-B | Cyanoacrylate compositions | 汉高知识产权控股有限责任公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-105246872-A | Cyanoacrylate compositions | Henkel US IP LLC | 2016-01-13 | — | — | CN | disclosed |
| US-20080293872-A1 | ADHESIVES, SEALANTS AND COATINGS CONTAINING GLASS PARTICLES AS A FILLER | HENKEL AG & CO. KGAA (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080287574-A1 | ADHESIVES, SEALANTS AND COATINGS CONTAINING GLASS PARTICLES AS A FILLER | HENKEL AG & CO. KGAA (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20060210528-A1 | Therapy for tropical diseases | ASPIRE BIOTECH, INC. | 2006-09-21 | — | — | US | disclosed |
| US-20030143189-A1 | Therapy for topical diseases | ASPIRE BIOTECH, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003041686-A2 | IMPROVED THERAPY FOR TOPICAL DISEASES | MEDLOGIC GLOBAL LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210528-A1 | Therapy for tropical diseases | TSLP, TLR3, CUTA | ATM 4347/4885HCAR2 2965/4885HPGD 1243/4885 |
| US-20030143189-A1 | Therapy for topical diseases | TSLP, KRT18, CUTA | ATM 4471/4885HCAR2 2700/4885HPGD 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.